PCRX vs PNTG

PCRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating a lack of strong fundamental momentum. The stock is severely overvalued relative to its deterministic baselines, trading at $23.86 despite a Graham Number of $7.79 and an Intrinsic Value of $1.12. While the balance sheet remains liquid with a current ratio of 4.54, the company is facing a crisis in profitability with earnings growth plummeting by 88.40% YoY. The massive discrepancy between the trailing P/E (149.12) and forward P/E (6.83) suggests the market is pricing in a recovery that is not yet supported by current growth metrics or insider activity.

PNTG exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and explosive growth metrics, though it currently trades at a premium to its Graham Number ($13.43) and Intrinsic Value ($24.78). The company is experiencing massive YoY revenue and earnings growth exceeding 53%, which justifies the current P/E expansion and the significant drop in Forward P/E (19.39). While the valuation is stretched relative to defensive benchmarks, the strong analyst consensus and operational momentum suggest further upside toward the $38.17 target. However, the narrow profit margins and heavy reliance on Medicare reimbursement remain primary headwinds.